Literature DB >> 18234884

Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals.

Rita Nyilas1, Barna Dudok, Gabriella M Urbán, Ken Mackie, Masahiko Watanabe, Benjamin F Cravatt, Tamás F Freund, István Katona.   

Abstract

Endocannabinoids are regarded as retrograde signaling molecules at various types of synapses throughout the CNS. The lipid derivatives anandamide and 2-arachidonoylglycerol (2-AG) are generally thought to be the key molecular players in this process. Previous anatomical and electrophysiological studies provided compelling evidence that the biosynthetic enzyme of 2-AG is indeed localized in the postsynaptic plasma membrane, whereas its target, the CB1 cannabinoid receptor, and the enzyme responsible for its inactivation are both found presynaptically. This molecular architecture of 2-AG signaling is a conserved feature of most synapses and supports the retrograde signaling role of 2-AG. Conversely, the molecular and neuroanatomical organization of synaptic anandamide signaling remains largely unknown. In contrast to its predicted role in retrograde signaling, here we show that N-acylphosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD), a biosynthetic enzyme of anandamide and its related bioactive congeners, the N-acylethanolamines (NAEs), is concentrated presynaptically in several types of hippocampal excitatory axon terminals. Furthermore, high-resolution quantitative immunogold labeling demonstrates that this calcium-sensitive enzyme is localized predominantly on the intracellular membrane cisternae of axonal calcium stores. Finally, the highest density of NAPE-PLD is found in mossy terminals of granule cells, which do not express CB1 receptors. Together, these findings suggest that anandamide and related NAEs are also present at glutamatergic synapses, but the sites of their synthesis and action are remarkably different from 2-AG, indicating distinct physiological roles for given endocannabinoids in the regulation of synaptic neurotransmission and plasticity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234884      PMCID: PMC6671412          DOI: 10.1523/JNEUROSCI.5102-07.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

Review 1.  Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.

Authors:  Megan L Fitzgerald; Eli Shobin; Virginia M Pickel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-11       Impact factor: 5.067

Review 2.  Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Authors:  Sergi Ferré; Carme Lluís; Zuzana Justinova; César Quiroz; Marco Orru; Gemma Navarro; Enric I Canela; Rafael Franco; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight.

Authors:  Vincenzo Di Marzo
Journal:  Nat Neurosci       Date:  2011-01       Impact factor: 24.884

Review 4.  Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know.

Authors:  Bradley E Alger
Journal:  J Physiol       Date:  2012-01-30       Impact factor: 5.182

Review 5.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 6.  The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders.

Authors:  Ismael Galve-Roperh; Javier Palazuelos; Tania Aguado; Manuel Guzmán
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-09       Impact factor: 5.270

Review 7.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 8.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

10.  Excitatory afferents to CA3 pyramidal cells display differential sensitivity to CB1 dependent inhibition of synaptic transmission.

Authors:  Mackenzie E Hofmann; Ben Nahir; Charles J Frazier
Journal:  Neuropharmacology       Date:  2008-07-15       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.